Questions in Topic
- 1. DSM-5 Classification for Substance Use Disorders
- 2. DSM-5 Criteria for Diagnosis of Substance Use Disorder
- 3. Percentage of U.S. Population with Substance Use Disorder
- 4. Estimates of Substance Use Disorders in Persons with HIV
- 5. Substance Use Disorders and HIV Transmission
- 6. Tobacco Smoking Cessation
- 7. Medications to Treat Alcohol Use Disorder
- 8. Buprenorphine-Naloxone for Opioid Use Disorder
- 9. Treatment of Stimulant Use Disorder
- 10. Methadone and Adverse Effects
A 62-year-old cisgender man with HIV recently had a visit to the emergency room for evaluation of chest pain. He had a follow-up outpatient stress test that was limited due to poor exercise tolerance. For approximately 30 years, he has smoked about one pack of cigarettes per day. For the first time, he is serious about quitting smoking.
Which one of the following statements is TRUE regarding smoking cessation?
Since you are not signed in, your progress won't be saved.
October 1st, 2023
Least Difficult
Population | Recommendation | Grade |
---|---|---|
Adults who are not pregnant | The USPSTF recommends that clinicians ask all adults about tobacco use, advise them to stop using tobacco, and provide behavioral interventions and U.S. Food and Drug Administration (FDA)-approved pharmacotherapy for cessation to adults who use tobacco. |
A |
Pregnant women | The USPSTF recommends that clinicians ask all pregnant women about tobacco use, advise them to stop using tobacco, and provide behavioral interventions for cessation to pregnant women who use tobacco. |
A |
Pregnant women | The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of pharmacotherapy interventions for tobacco cessation in pregnant women. |
I |
All adults, including pregnant women | The USPSTF concludes that the current evidence is insufficient to recommend electronic nicotine delivery systems (ENDS) for tobacco cessation in adults, including pregnant women. The USPSTF recommends that clinicians direct patients who smoke tobacco to other cessation interventions with established effectiveness and safety (previously stated). |
I |
- Siu AL. Behavioral and Pharmacotherapy Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Women: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2015;163:622-34. [PubMed Abstract]
Drug (doses) |
How Sold (U.S.) | Dosing Instructions | Administration | Common Side Effects | Advantages | Disadvantages |
---|---|---|---|---|---|---|
Nicotine patch 21 mg 14 mg 7 mg |
OTC or Rx |
Starting dose: 21 mg for ≥10 cigarettes per day. 14 mg for <10 cigarettes per day. After 6 weeks, option to taper to lower doses for 2-6 weeks. Use ≥3 months. After 6 weeks, continue original dose or taper to lower doses (either option acceptable). |
Apply a new patch each morning to dry skin. Rotate application site to avoid skin irritation. May start patch before or on quit date. Keep using even if a slip occurs. If insomnia or disturbing dreams, remove patch at bedtime. |
Skin irritation Trouble sleeping Vivid dreams (patch can be removed at bedtime to manage insomnia or vivid dreams) |
The easiest nicotine product to use. Provides a steady nicotine level. Combination NRT therapy: as needed, can add gum, lozenge, inhaler, or nasal spray to patch to cover situational cravings. |
User cannot alter dose if cravings occur during the day. |
Nicotine lozenge 4 mg 2 mg |
OTC or Rx |
If first cigarette is ≤30 minutes of waking: 4 mg. If first cigarette is >30 minutes of waking: 2 mg. Use ≥3 months. |
Place between gum and cheek, let it melt slowly. Use 1 piece every 1-2 hours (Max: 20/day). |
Mouth
irritation Hiccups Heartburn Nausea |
User controls nicotine dose. Oral substitute for cigarettes. May be added to patch to cover situational cravings. Easier to use than gum for those with dental work or dentures. |
No food or drink 15 minutes prior to use and during use. |
Nicotine gum 4 mg 2 mg |
OTC or Rx | If first cigarette is ≤30 minutes of waking: 4
mg. If first cigarette is >30 minutes of waking: 2 mg. Use ≥3 months. |
Chew briefly until mouth tingles, then
‘park’ gum inside cheek until tingle fades. Repeat chew-and-park each time tingle fades. Discard gum after 30 minutes of use. Use ~ 1 piece per hour (Max: 24/day). |
Mouth irritation Jaw soreness Heartburn Hiccups Nausea |
User controls nicotine dose. Oral substitute for cigarettes. May be added to patch to cover situational cravings. |
Not chewed in same way as
regular gum; requires careful instruction. Can damage dental work and be difficult to use with dentures. No food or drink 15 minutes prior to use and during use. |
Nicotine inhaler 10-mg cartridge |
Rx only |
10 mg/cartridge. Each cartridge has ~80 puffs. Use ≥3 months. |
Puff into mouth/throat until cravings subside. Do not inhale into lungs. Change cartridge when nicotine taste disappears. Use 1 cartridge every 1-2 hours (Max: 16/day). |
Mouth and throat irritation Coughing if inhaled too deeply |
User controls nicotine dose. Mimics hand-to-mouth ritual of smoking cigarettes.May be added to patch to cover situational cravings. |
Frequent puffing required. |
Nicotine nasal spray 10 mg/mL (10 mL bottle) |
Rx only |
10 mg/mL. 0.5 mg per spray. Each bottle has ~200 sprays. Use ≥3 months. |
Use 1 spray to each nostril. Use spray every 1-2 hours (Max: 80/day). |
Nasal and throat irritation Rhinitis Sneezing Coughing Tearing |
User controls nicotine dose. Most rapid delivery of nicotine among all NRT products. May be added to patch to cover situational cravings. |
Has the most side effects of all NRT products. Some users cannot tolerate local irritation to nasal mucosa. |
Varenicline (tablet) 0.5 mg 1.0 mg |
Rx only |
Days 1-3: 0.5 mg/day. Days 4-7: 0.5 mg twice a day. Day 8+: 1 mg twice a day. Use 3-6 months. |
Start 1-4 weeks before quit date. Take with food and a tall glass of water to minimize nausea. |
Nausea Insomnia Vivid dreams Headache |
Quit date can be flexible, from 1 week to 3 months after starting drug. Dual action:relieves nicotine withdrawal and blocks reward of smoking. Oral agent (pill). |
Because of previous FDA warning (now removed), many patients fear psychiatric adverse events, even though they are no more common than with other cessation medications. |
Bupropion sustained release (SR) (tablet) 150 mg |
Rx only |
150 mg/day for 3 days, then 150 mg twice a day. Use 3-6 months. |
Start 1-2 weeks before quit date. |
Insomnia Agitation Dry mouth Headache |
May lessen post-cessation weight gain while drug is being taken. Oral agent (pill). |
Increases seizure risk: not for use if seizure disorder or binge drinking. |
* All are FDA-approved as smoking cessation aids and listed as a first-line medication by U.S. Clinical Practice Guidelines (Fiore, 2008) + Recommended duration of use for medications is at least 3 months but extending dose to 6 months is frequently done to prevent relapse to tobacco use. Patching dosing differs slightly from FDA labeling. Abbreviations: FDA = U.S. Food and Drug Administration; NRT = nicotine replacement therapy; OTC = over the counter (no prescription required); Rx = prescription required. |
- Barua RS, Rigotti NA, Benowitz NL, et al. 2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2018;72:3332-65. [PubMed Abstract]